EQT Life Sciences invests in biotech company Asceneuron
Asceneuron develops small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease.
16 July 2024•2 mins read
Asceneuron develops small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease.
GrowthCurve Capital takes majority stake in medication access platform TailorMed
6 hours ago · 1 min read
OpenGate Capital completes carve-out of Maersk Training from Maersk
8 hours ago · 1 min read
Stonepeak completes acquisition of 65% Castrol stake from BP
9 hours ago · 1 min read
Livingbridge backs launch of accounting group Apteus after seven acquisitions
11 hours ago · 2 mins read
DPE-backed CirQono acquires Saxony demolition firm ORA in add-on deal
14 hours ago · 2 mins read
Charterhouse agrees to sell Vermeg stake to Advent, with ADIA co-investing
15 hours ago · 2 mins read
Apollo funds complete minority investment in Alpine-backed Apex Service Partners
30 October 2026 · 2 mins read
